Appendix cancer laboratory findings

Jump to: navigation, search

Appendix cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Differentiating Appendix cancer from other Diseases

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

MRI

CT scan

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Appendix cancer laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Appendix cancer laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Appendix cancer laboratory findings

CDC on Appendix cancer laboratory findings

Appendix cancer laboratory findings in the news

Blogs on Appendix cancer laboratory findings

Directions to Hospitals Treating Appendix cancer

Risk calculators and risk factors for Appendix cancer laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]

Overview

There are no diagnostic laboratory findings associated with appendix cancer in general. Laboratory findings consistent with the diagnosis of carcinoid tumors include , Chromogranin A (CgA), 5-HIAA (5-hydroxyindoleacetic acid) as well as Ki67. Some patients with colonic type adenocarcinoma may have elevated concentration of CEA and CA 19-9.

Laboratory Findings

References

  1. Carmignani CP, Hampton R, Sugarbaker CE, Chang D, Sugarbaker PH (2004) Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J Surg Oncol 87 (4):162-6. DOI:10.1002/jso.20107 PMID: 15334630
  2. Oberg K, Janson ET, Eriksson B (1999) Tumour markers in neuroendocrine tumours. Ital J Gastroenterol Hepatol 31 Suppl 2 ():S160-2. PMID: 10604122
  3. Gut P, Czarnywojtek A, Fischbach J, Bączyk M, Ziemnicka K, Wrotkowska E et al. (2016) Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls. Arch Med Sci 12 (1):1-9. DOI:10.5114/aoms.2016.57577 PMID: 26925113
  4. 4.0 4.1 Maroun J, Kocha W, Kvols L, Bjarnason G, Chen E, Germond C et al. (2006) Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Curr Oncol 13 (2):67-76. PMID: 17576444
  5. Eriksson B, Oberg K, Stridsberg M (2000) Tumor markers in neuroendocrine tumors. Digestion 62 Suppl 1 ():33-8. DOI:10.1159/000051853 PMID: 10940685
  6. Oberg K (2003) Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther 3 (6):863-77. DOI:10.1586/14737140.3.6.863 PMID: 14686708